FR2834900B1 - NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS - Google Patents

NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS

Info

Publication number
FR2834900B1
FR2834900B1 FR0200654A FR0200654A FR2834900B1 FR 2834900 B1 FR2834900 B1 FR 2834900B1 FR 0200654 A FR0200654 A FR 0200654A FR 0200654 A FR0200654 A FR 0200654A FR 2834900 B1 FR2834900 B1 FR 2834900B1
Authority
FR
France
Prior art keywords
igf
applications
novel compositions
egfr activity
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0200654A
Other languages
French (fr)
Other versions
FR2834900A1 (en
Inventor
Liliane Goetsch
Nathalie Corvaia
Olivier Leger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0200654A priority Critical patent/FR2834900B1/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to ES03712270T priority patent/ES2283759T3/en
Priority to SI200330732T priority patent/SI1461359T1/en
Priority to CA2473039A priority patent/CA2473039C/en
Priority to AT03712270T priority patent/ATE357460T1/en
Priority to DE60312639T priority patent/DE60312639T2/en
Priority to JP2003560053A priority patent/JP4606739B2/en
Priority to AU2003216748A priority patent/AU2003216748B2/en
Priority to DK03712270T priority patent/DK1461359T3/en
Priority to EP06126429A priority patent/EP1798242B1/en
Priority to ES06126430T priority patent/ES2427964T3/en
Priority to EP06126430.5A priority patent/EP1806364B1/en
Priority to CNB038024489A priority patent/CN100410275C/en
Priority to PT03712270T priority patent/PT1461359E/en
Priority to MXPA04006980A priority patent/MXPA04006980A/en
Priority to PCT/FR2003/000178 priority patent/WO2003059951A2/en
Priority to BRPI0306973A priority patent/BRPI0306973B8/en
Priority to EP03712270A priority patent/EP1461359B1/en
Publication of FR2834900A1 publication Critical patent/FR2834900A1/en
Priority to US10/735,916 priority patent/US7241444B2/en
Priority to ZA2004/05402A priority patent/ZA200405402B/en
Priority to US11/012,353 priority patent/US7553485B2/en
Application granted granted Critical
Publication of FR2834900B1 publication Critical patent/FR2834900B1/en
Priority to HK05110480A priority patent/HK1078590A1/en
Priority to US11/783,513 priority patent/US7914784B2/en
Priority to US11/783,666 priority patent/US20080063639A1/en
Priority to US11/801,080 priority patent/US20080193445A1/en
Priority to CY20071100801T priority patent/CY1106662T1/en
Priority to US12/388,534 priority patent/US8101180B2/en
Priority to AU2009201674A priority patent/AU2009201674B2/en
Priority to JP2010124341A priority patent/JP2010233575A/en
Priority to US13/037,734 priority patent/US8168410B2/en
Priority to US13/352,599 priority patent/US8808999B2/en
Priority to US13/777,040 priority patent/US20130273031A1/en
Priority to US14/492,636 priority patent/US20150079080A1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
FR0200654A 2002-01-18 2002-01-18 NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS Expired - Lifetime FR2834900B1 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
FR0200654A FR2834900B1 (en) 2002-01-18 2002-01-18 NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS
AT03712270T ATE357460T1 (en) 2002-01-18 2003-01-20 ANTIBODIES TO IGF-IR AND THEIR USES
CA2473039A CA2473039C (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
BRPI0306973A BRPI0306973B8 (en) 2002-01-18 2003-01-20 anti-igf-ir antibodies, their production method and their uses, murine hybridoma, isolated nucleic acid, vector, composition, kit or kit, and in vitro diagnostic method of diseases induced by an overexpression or underexpression of the igf-ir receptor
DE60312639T DE60312639T2 (en) 2002-01-18 2003-01-20 ANTIBODIES TO IGF-IR AND ITS USES
JP2003560053A JP4606739B2 (en) 2002-01-18 2003-01-20 Novel anti-IGF-IR antibodies and uses thereof
AU2003216748A AU2003216748B2 (en) 2002-01-18 2003-01-20 Novel anti-IGF-IR antibodies and uses thereof
DK03712270T DK1461359T3 (en) 2002-01-18 2003-01-20 New anti-IGF-IR antibodies and their applications
EP06126429A EP1798242B1 (en) 2002-01-18 2003-01-20 Anti-IGF-IR antibodies and their applications
ES06126430T ES2427964T3 (en) 2002-01-18 2003-01-20 New anti-IGF-IR antibodies and their applications
EP06126430.5A EP1806364B1 (en) 2002-01-18 2003-01-20 New anti-IGF-IR antibodies and their applications
CNB038024489A CN100410275C (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
PT03712270T PT1461359E (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
MXPA04006980A MXPA04006980A (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof.
PCT/FR2003/000178 WO2003059951A2 (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
SI200330732T SI1461359T1 (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
ES03712270T ES2283759T3 (en) 2002-01-18 2003-01-20 ANTI-IGF-IR ANTIBODIES AND ITS APPLICATIONS.
EP03712270A EP1461359B1 (en) 2002-01-18 2003-01-20 Novel anti-igf-ir antibodies and uses thereof
US10/735,916 US7241444B2 (en) 2002-01-18 2003-12-16 Anti-IGF-IR antibodies and uses thereof
ZA2004/05402A ZA200405402B (en) 2002-01-18 2004-07-07 Novel anti-igf-ir antibodies and uses thereof
US11/012,353 US7553485B2 (en) 2002-01-18 2004-12-16 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
HK05110480A HK1078590A1 (en) 2002-01-18 2005-11-20 Novel anti-igf-ir antibodies and uses thereof
US11/783,513 US7914784B2 (en) 2002-01-18 2007-04-10 Anti-IGF-IR antibodies and uses thereof
US11/783,666 US20080063639A1 (en) 2002-01-18 2007-04-11 Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US11/801,080 US20080193445A1 (en) 2002-01-18 2007-05-08 Novel anti-IGF-IR antibodies and uses thereof
CY20071100801T CY1106662T1 (en) 2002-01-18 2007-06-15 ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
US12/388,534 US8101180B2 (en) 2002-01-18 2009-02-19 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
AU2009201674A AU2009201674B2 (en) 2002-01-18 2009-04-24 Novel anti-IGF-IR antibodies and uses thereof
JP2010124341A JP2010233575A (en) 2002-01-18 2010-05-31 Novel anti-igf-ir antibody and use thereof
US13/037,734 US8168410B2 (en) 2002-01-18 2011-03-01 Anti-IGF-IR antibodies and uses thereof
US13/352,599 US8808999B2 (en) 2002-01-18 2012-01-18 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US13/777,040 US20130273031A1 (en) 2002-01-18 2013-02-26 Novel anti-igf-ir antibodies and uses thereof
US14/492,636 US20150079080A1 (en) 2002-01-18 2014-09-22 Novel anti-igf-ir antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0200654A FR2834900B1 (en) 2002-01-18 2002-01-18 NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS

Publications (2)

Publication Number Publication Date
FR2834900A1 FR2834900A1 (en) 2003-07-25
FR2834900B1 true FR2834900B1 (en) 2005-07-01

Family

ID=27619550

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0200654A Expired - Lifetime FR2834900B1 (en) 2002-01-18 2002-01-18 NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS

Country Status (1)

Country Link
FR (1) FR2834900B1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484000A1 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
ATE514783T1 (en) 2003-11-12 2011-07-15 Schering Corp PLASMID SYSTEM FOR EXPRESSING MULTIPLE GENES
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
EP2283831A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
EP2032989B2 (en) 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Igfbp2 biomarker
CA2672828A1 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110927A (en) * 2000-05-19 2003-03-11 Scancell Ltd Antibody, nucleic acid, vector, cell, method of making an antibody, pharmaceutical composition, use of an antibody or nucleic acid, and method for treating or prophylaxis of cancer
CA2433800C (en) * 2001-01-05 2016-09-13 Pfizer Inc. Antibodies to insulin-like growth factor i receptor

Also Published As

Publication number Publication date
FR2834900A1 (en) 2003-07-25

Similar Documents

Publication Publication Date Title
DZ3491A1 (en) INDANYL ACYLATED AMINES AND THEIR USE AS PHARMACEUTICAL AGENTS
DK1620118T3 (en) REVERSIBLE PEGYLED MEDICINAL PRODUCTS
FR12C0019I2 (en) O-CYCLOPROPYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES
DE60317699D1 (en) FERMENTATION PROCESSES AND COMPOSITIONS
IS2504B (en) Phosphonooxyquinazoline derivatives and their pharmaceutical uses
NO20052278L (en) Piperazinyl and diazapanyl benzamides and benzthioamides
DE60324099D1 (en) DRUG-CONTAINING TAMPON
LTPA2013018I1 (en) 4-OXOQUINOLINE COMPOUNDS AND THEIR USE AS HIV INGREGATE INHIBITORS
IS8074A (en) Substituted 1,4- Diazepines and their use
DE60333495D1 (en) WOUND AND SKIN CARE COMPOSITIONS
DE60326611D1 (en) N AND THE EQUAL
PT1501534E (en) PHARMACEUTICAL FORMULATIONS
FR2849381B1 (en) COSMETIC, SOLAR AND BIO-BRONZING COMPOSITION
ATE411345T1 (en) TEXTILE CARE PRODUCTS
FR2845287B1 (en) NOVEL COSMETIC FORMULATIONS BASED ON A THICKENING AGENT AND THEIR APPLICATIONS
IS7829A (en) New 1,4-diazabicycloalkane derivatives, their production and use
DE60316300D1 (en) ROOT SPECIFIC PROMOTERS AND THEIR USES
DE60335143D1 (en) ORAL CARE COMPOSITIONS AND METHODS
ATE388935T1 (en) N-ALKYNYL-2-(SUBSTITUTED PHENOXY)-ALKYLAMIDES AND THEIR USE AS FUNGICIDES
FR2834900B1 (en) NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS
DE60228468D1 (en) ARTIFICIAL TEETH AND THEIR PRODUCTION
IS7961A (en) Diarylmethylidene piperidine derivatives, their formulations and their use
DE50310363D1 (en) BLUE 3H-NAPHTHO2,1-B-PYRAN DERIVATIVES AND THEIR USE
FR2834991B1 (en) NEW ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
FR2850969B1 (en) ACYLATED AMINOPROPANEDIOLS AND THE LIKE AND THEIR THERAPEUTIC USES

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20